What should be done to tackle ghostwriting in the medical literature?

PLoS Medicine

Volumn 6, Issue 2, 2009, Pages 0122-0125

  Gøtzsche, Peter C ^a   Kassirer, Jerome P ^b,c,d   Woolley, Karen L ^e,f   Wager, Elizabeth ^g   Jacobs, Adam ^h   Gertel, Art ⁱ   Hamilton, Cindy ^j  

^a Nordic Cochrane Centre   (Denmark)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d New England Journal of Medicine   (United States)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f ProScribe Medical Communications   (Australia)

^g Sideview   (United Kingdom)

^h Dianthus Medical Limited   (United Kingdom)

ⁱ Beardsworth Consulting Group Inc   (United States)

^j Hamilton House   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; MEDICAL LITERATURE; MEDICAL RESEARCH; PUBLICATION; SCIENTIFIC MISCONDUCT; SHORT SURVEY; ARTICLE; ETHICS; HUMAN; INTERPERSONAL COMMUNICATION; PUBLISHING; WRITING;

AUTHORSHIP; BIOMEDICAL RESEARCH; DISCLOSURE; EDITORIAL POLICIES; HUMANS; PERIODICALS AS TOPIC; SCIENTIFIC MISCONDUCT;

EID: 61449122945     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000023     Document Type: Short Survey

References (25)

1. Angell M (2004) The truth about the drug companies: How they deceive us and what to do about it. New York: Random House. 336 p.
2. Kassirer JP (2005) On the take: How medicine's complicity with big business can endanger your health. Oxford: Oxford University Press. 272 p.
3. Smith R (2006) The trouble with medical journals. London: Royal Society of Medicine Press. 292 p.
4. World Association of Medical Editors (2005) Ghost writing initiated by commercial companies. Available: http://www.wame.org/resources/policies#ghost. Accessed 29 December 2008.
5. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, et al. (2007) Ghost authorship in industry-initiated randomised trials. PLoS Med 4: e19. doi:10.1371/journal.pmed.0040019
6. Ross JS, Hill KP, Egilman DS, Krumholz HM (2008) Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. JAMA 299: 1800-1812.
7. Danish Ministry of Science, Technology and Innovation (2005) Bekendtgørelse om udvalgene vedrørende videnskabelig uredelighed. Available: https://www.retsinformation.dk/Forms/R07l0.aspx?id=29238.Accessed 29 December 2008.
8. Rennie D, Yank V, Emanuel L (1997) When authorship fails: A proposal to make contributors accountable. JAMA 278: 579-585.
9. Wager E, Field EA, Grossman L (2003) Good publication practice for pharmaceutical companies. Curr Med Res Opin 19: 149-154. Available: http://www.gpp-guidelines.org/.Accessed 29 December 2008.
10. International Committee of Medical Journal Editors (2008) Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication. Available: http://www.icmje.org/.Accessed 29 December 2008.
11. Wager E (2007) Authors, ghosts, damned lies, and statisticians. PLoS Med 4:e34. doi:10.1371/journal.pmed.0040034
12. Smith R (2005) Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2: e138. doi:10.1371/journal.pmed.0020138
13. Smith R, Roberts I (2006) Patient safety requires a new way to publish clinical trials. PLOS Clin Trial 1: e6. doi:10.1371/journal.pctr.0010006
14. Flanagin A, Carey LA, Fontanarosa PB, Phillips SG, Pace BP, et al. (1998) Prevalence of articles with ghost authors and ghost authors in peer-reviewed medical journals. JAMA 280: 222-224.
15. Mowatt G, Shirran L, Grinshaw JM, Rennie D, Flanagin A, et al. (2002) Prevalence of honorary and ghost authorship in Cochrane reviews. JAMA 287: 2769-2771.
16. Woolley KL, Ely JA, Woolley MJ, Findlay L, Lynch FA, et al. (2006) Declaration of medical writing assistance in international peer-reviewed publications. JAMA 296: 932-934.
17. Martinson BC, Anderson MS, deVries R (2005) Scientists behaving badly. Nature 435: 737-738.
18. Woolley KL (2006) Goodbye ghostwriters!: How to work ethically and efficiently with professional medical writers. Chest 130: 921-923.
19. Griffin-Sobel JP (2005) The status of peer review. Clin J Oncol Nurs 9:669.
20. Scherer RW, Langenberg P, von Elm E (2007) Full publication of results initially presented in abstracts. Cochrane Database Syst Rev: MR000005.
21. Norris R, Bowman A, Fagan JM, Gallagher ER, Geraci AB, et al. (2007) International Society for Medical Publication Professionals (ISMPP) position statement: The role of the professional medical writer. Curr Med Res Opin 23: 1837-1840.
22. Rising K, Bacchetti P, Bero L (2008) Reporting bias in drug trials submitted to the Food and Drug Administration: Review of publication and presentation. PLoS Med 5: e217. doi:10.1371/journal.pmed.0050217
23. Hamilton CW, Royer MG (2003) AMWA position statement on the contributions of medical writers to scientific publications. AMWA J 18: 13-15.
24. Jacobs A, Wager E (2005) European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. Curr Med Res Opin 21: 317-322.
25. Pharmaceutical Research and Manufacturers of America (2004) Principles on conduct of clinical trials and communication of clinical trial results. Available: http://www.phrma.org/files/Clinical%20Trials.pdf. Accessed 29December 2008.